Novartis announces plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
- New clinical trial to evaluate Jakavi??(ruxolitinib) in patients with COVID-19 associated cytokine storm?
- Cytokine storm is a type of severe immune overreaction that can result from coronavirus infection and may contribute to respiratory compromise in patients with COVID-191-3
- Pre-clinical and preliminary clinical evidence suggests Jakavi, a well-established JAK inhibitor, could reduce the number of patients requiring intensive care and mechanical ventilation
- Novartis to establish compassionate use program for COVID-19 patient access and undertake steps to ensure uninterrupted supply of Jakavi for currently licensed indications